These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19923222)

  • 1. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.
    Basi GS; Feinberg H; Oshidari F; Anderson J; Barbour R; Baker J; Comery TA; Diep L; Gill D; Johnson-Wood K; Goel A; Grantcharova K; Lee M; Li J; Partridge A; Griswold-Prenner I; Piot N; Walker D; Widom A; Pangalos MN; Seubert P; Jacobsen JS; Schenk D; Weis WI
    J Biol Chem; 2010 Jan; 285(5):3417-27. PubMed ID: 19923222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
    Moretto N; Bolchi A; Rivetti C; Imbimbo BP; Villetti G; Pietrini V; Polonelli L; Del Signore S; Smith KM; Ferrante RJ; Ottonello S
    J Biol Chem; 2007 Apr; 282(15):11436-45. PubMed ID: 17267402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.
    Zago W; Buttini M; Comery TA; Nishioka C; Gardai SJ; Seubert P; Games D; Bard F; Schenk D; Kinney GG
    J Neurosci; 2012 Feb; 32(8):2696-702. PubMed ID: 22357853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain.
    Hatami A; Albay R; Monjazeb S; Milton S; Glabe C
    J Biol Chem; 2014 Nov; 289(46):32131-32143. PubMed ID: 25281743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
    Dong H; Csernansky CA; Martin MV; Bertchume A; Vallera D; Csernansky JG
    Psychopharmacology (Berl); 2005 Aug; 181(1):145-52. PubMed ID: 15778881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease amyloid-β pathology in the lens of the eye.
    Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
    Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.
    Solomon B
    DNA Cell Biol; 2001 Nov; 20(11):697-703. PubMed ID: 11788047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.
    Gonzalez-Castro R; Acero Galindo G; García Salcedo Y; Uribe Campero L; Vazquez Perez V; Carrillo-Tripp M; Gevorkian G; Gomez Lim MA
    Inflammopharmacology; 2018 Jun; 26(3):817-827. PubMed ID: 29094307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model.
    Mouri A; Noda Y; Hara H; Mizoguchi H; Tabira T; Nabeshima T
    FASEB J; 2007 Jul; 21(9):2135-48. PubMed ID: 17341681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Cattepoel S; Hanenberg M; Kulic L; Nitsch RM
    PLoS One; 2011 Apr; 6(4):e18296. PubMed ID: 21483675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.
    Manczak M; Mao P; Nakamura K; Bebbington C; Park B; Reddy PH
    Hum Mol Genet; 2009 Oct; 18(20):3876-93. PubMed ID: 19617638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease.
    Wati H; Kawarabayashi T; Matsubara E; Kasai A; Hirasawa T; Kubota T; Harigaya Y; Shoji M; Maeda S
    Brain Pathol; 2009 Jan; 19(1):48-57. PubMed ID: 18429966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model.
    Fukuchi K; Accavitti-Loper MA; Kim HD; Tahara K; Cao Y; Lewis TL; Caughey RC; Kim H; Lalonde R
    Biochem Biophys Res Commun; 2006 May; 344(1):79-86. PubMed ID: 16630540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.
    Movsesyan N; Davtyan H; Mkrtichyan M; Petrushina I; Tiraturyan T; Ross T; Agadjanyan MG; Ghochikyan A; Cribbs DH
    Hum Gene Ther; 2010 Nov; 21(11):1569-76. PubMed ID: 20528468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
    Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
    Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.